TG Therapeutics, Inc. (TGTX)
Stock Price Chart
Key Info
| Market Cap | 2.61B |
| Revenue (ttm) | 152,000 |
| Net Income (ttm) | -205.50M |
| Shares Out | 126.65M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $20.64 |
| Previous Close | $20.38 |
| Change ($) | 0.26 |
| Change (%) | 1.28% |
| Day's Open | 19.05 |
| Day's Range | 20.36 - 20.64 |
| Day's Volume | 72,336 |
| 52-Week Range | 4.95 - 24.76 |
More Stats
| Market Cap | 2.61B |
| Enterprise Value | 2.38B |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 126.65M |
| Float | 93.43M |
| EPS (basic) | -2.05 |
| EPS (diluted) | -2.04 |
| FCF / Share | -1.51 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 14.54M |
| Short Ratio | 9.16 |
| Short % of Float | 15.13% |
| Beta | 2.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 17,197.60 |
| PB Ratio | 12.05 |
| Revenue | 152,000 |
| Operating Income | -199.91M |
| Net Income | -205.50M |
| Free Cash Flow | -169.76M |
| Net Cash | 237.45M |
| Net Cash / Share | 1.87 |
| Gross Margin | 100.00% |
| Operating Margin | -131,521.05% |
| Profit Margin | -135,198.70% |
| FCF Margin | -111,681.58% |
| ROA | -62.29% |
| ROE | -198.14% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.02 | - | - |
| Revenue Growth | 0% | 0% | 0% | 0% | 0% | -0.25% | 699.98% | - | - | - |
| Gross Profit | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.02 | - | - |
| Operating Income | -169 | -174 | -119 | -78.97 | -63.18 | -55.72 | -22.97 | -26.90 | -0.88 | -2.02 |
| Net Income | -173 | -173 | -118 | -78.25 | -62.95 | -55.78 | -20.48 | -18.07 | -0.85 | 0.62 |
| Shares Outstanding | 88.37 | 75.47 | 62.07 | 54.73 | 45.65 | 34.07 | 25.41 | 13.11 | 1.93 | 0.04 |
| Earnings Per Share | -1.96 | -2.30 | -1.91 | -1.60 | -1.38 | -1.64 | -0.81 | -1.38 | -0.44 | 16.87 |
| Operating Cash Flow | -133 | -129 | -93.76 | -61.59 | -44.69 | -35.06 | -10.74 | -5.19 | -0.09 | -1.97 |
| Capital Expenditures | -0.13 | -0.09 | - | -0.34 | -0.04 | -0.02 | -0.01 | - | - | - |
| Free Cash Flow | -133 | -129 | -93.76 | -61.93 | -44.73 | -35.08 | -10.74 | -5.19 | -0.09 | -1.97 |
| Cash & Equivalents | 142 | 70.14 | 85.30 | 45.47 | 77.81 | 79.35 | 40.49 | 16.46 | 9.75 | 0.48 |
| Total Debt | 39.19 | - | 0.13 | 0.07 | 0.21 | 0.28 | 0.74 | 3.16 | 4.17 | 18.18 |
| Net Cash / Debt | 102 | 70.14 | 85.18 | 45.40 | 77.60 | 79.08 | 39.74 | 13.30 | 5.58 | -17.71 |
| Assets | 163 | 83.62 | 97.38 | 54.78 | 113 | 86.75 | 48.11 | 22.07 | 14.54 | 18.64 |
| Liabilities | 124 | 59.58 | 30.39 | 18.91 | 11.90 | 6.65 | 8.06 | 6.52 | 4.90 | 24.00 |
| Book Value | 38.62 | 24.04 | 66.99 | 35.87 | 102 | 80.10 | 40.05 | 15.55 | 9.62 | -5.36 |
Company Profile
Company Details
| Full Name | TG Therapeutics, Inc. |
| Country | United States |
| Employees | 134 |
| CEO | Michael Sean Weiss |
Stock Information
| Ticker Symbol | TGTX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: TGTX |
| IPO Date | December 14, 1995 |
Description
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.